Inhibitors of Hepatitis C Virus NS3.4A Protease: P2 Proline Variants

Author(s): Luc J. Farmer, Shawn D. Britt, Kevin M. Cottrell, John J. Court, Lawrence F. Courtney, David D. Deininger, Cynthia A. Gates, Scott L. Harbeson, Kai Lin, Chao Lin, Yu- P. Luong, John P. Maxwell, Janos Pitlik, B. G. Rao, Wayne C. Schairer, John A. Thomson, Roger D. Tung, John H. Van Drie, Yunyi Wei, Robert B. Perni.

Journal Name: Letters in Drug Design & Discovery

Volume 2 , Issue 7 , 2005

Become EABM
Become Reviewer

Abstract:

A series of novel bicyclic proline P2 scaffold based tetrapeptide inhibitors were designed and prepared. Given their relatively small size, these compounds exhibited exceptional binding affinities and good cellular potencies for HCV protease. One of the best analogues, tricyclic based P2 scaffold 12, had an affinity for HCV with a Ki of 37 nM and cell activity IC50 of 200 nM.

Keywords: Hepatitis C, NS3, •, 4A protease, tetrapeptide inhibitors, VX-950, bicyclic proline, P2 scaffolds

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 2
ISSUE: 7
Year: 2005
Page: [497 - 502]
Pages: 6
DOI: 10.2174/157018005774479203
Price: $58

Article Metrics

PDF: 6